HOXA1-IN-1
HOXA1-IN-1 is a HOXA1 inhibitor. HOXA1-IN-1 downregulates HOXA1 protein levels, suppresses its transcriptional activity, and alters the expression of its downstream target genes. HOXA1-IN-1 induces DNA damage and apoptosis in cancer cells. HOXA1-IN-1 exhibits antitumor efficacy in xenograft models of colorectal cancer and triple-negative breast cancer. HOXA1-IN-1 shows synergistic activity in combination with Cisplatin (HY-17394). HOXA1-IN-1 can be used for the research of colorectal cancer and triple-negative breast cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 3118854-61-5
- 分子式: C23H31NO2
- 分子量:353.50
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
体外実験
HOXA1-IN-1 (F2-15) directly binds to HOXA1 protein in intact cells[1].
HOXA1-IN-1 (48 h) potently inhibits the viability of MCF-7, HCT116, and HepG2 cancer cells with IC50 values of 5.23 μM, 24.27 μM, and 14.18 μM, respectively[1].
HOXA1-IN-1 (10 μM; 24 h) inhibits DNA synthesis and cell proliferation in an HOXA1-dependent manner, reducing EdU-positive cell fractions in wild-type MCF-7, HCT116, HepG2, MDA-MB-231, and HCT116 cells, but having no effect in HOXA1-knockdown cells[1].
HOXA1-IN-1 (10 μM; 24 h) induces DNA damage and apoptosis in MCF-7, HCT116, and HepG2 cancer cells[1].
HOXA1-IN-1 (10 μM; 24 h) does not alter HOXA1 mRNA levels but suppresses the expression of HOXA1 downstream target genes SMAD3, KHDRBS1, SHC1, and SFXN3 in MCF-7, HCT116, and HepG2 cells[1].
HOXA1-IN-1 (10 μM; 24 h) downregulates HOXA1 protein expression in MCF-7, HCT116, and HepG2 cancer cells[1].
HOXA1-IN-1 (4 days) exhibits strong synergistic antiproliferative activity with Cisplatin (HY-17394) in HCT116 and MDA-MB-231 cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7, HCT116, HepG2, MDA-MB-231, HOXA1-knockdown MDA-MB-231, HOXA1-knockdown HCT116 cell lines
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Reduced the fraction of EdU-positive cells by 60-80% in MCF-7, HCT116, HepG2, and wild-type MDA-MB-231 and HCT116 cells.
Did not significantly reduce EdU-positive cell fractions in HOXA1-knockdown MDA-MB-231 and HCT116 cells.
-
Cell Line:MCF-7, HCT116, HepG2 cell lines
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly increased the percentage of TUNEL-positive cells in all three cell lines: MCF-7, HCT116, and HepG2, with TUNEL-positive fractions increasing from < 5% in controls to ~10-20% in treated cells.
-
Cell Line:MCF-7, HCT116, HepG2 cell lines
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Had no significant effect on HOXA1 mRNA levels in any of the three cell lines.
Significantly downregulated the mRNA expression of HOXA1 target genes SMAD3, KHDRBS1, SHC1, and SFXN3 in all three cell lines.
-
Cell Line:MCF-7, HCT116, HepG2 cell lines
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly reduced HOXA1 protein levels in MCF-7, HCT116, and HepG2 cells, with visible decreases in HOXA1 band intensity relative to TUBLIN loading control.
体内実験
HOXA1-IN-1 (20 mg/kg; i.p.; once daily; 14 days) in combination with Cisplatin (HY-17394) produces a synergistic antitumor effect in female nu/nu mice bearing colorectal cancer PDXs and female nu/nu mice bearing triple-negative breast cancer PDXs, resulting in greater tumor growth inhibition than either agent alone[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:female nu/nu mice (6-week-old, subcutaneously transplanted xenografts)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; once daily; 14 days
-
Result:Reduced tumor weights compared to vehicle control, with levels comparable to cisplatin.
Reduced tumor volume growth over time compared to vehicle control.
Reduced HOXA1 and Ki67 (proliferation marker) expression in tumor tissue compared to vehicle control.
Increased caspase-3 staining (apoptosis marker) in tumor tissue compared to vehicle control.
-
Animal Model:female nu/nu mice (6-week-old, subcutaneously transplanted xenografts)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; once daily; 14 days
-
Result:Reduced tumor weights compared to vehicle control, with levels comparable to cisplatin.
Reduced tumor volume growth over time compared to vehicle control.
Reduced HOXA1 and Ki67 (proliferation marker) expression in tumor tissue compared to vehicle control.
Increased caspase-3 staining (apoptosis marker) in tumor tissue compared to vehicle control.
化学情報
-
CAS 番号 3118854-61-5
-
分子量 353.50
-
分子式 C23H31NO2
-
SMILES
CC1=CC(C)=CC=C1NC(C2=C(O)C=CC(C(C)(C)CC(C)(C)C)=C2)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
HOXA1-IN-1 関連分類
HY-181823 関連分類
Powered by Bioz